(Q36552307)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

meta-analysis

0 references

title

Progression-free survival as a surrogate endpoint in advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Björn Stollenwerk

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Uwe Siebert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Vera Zietemann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Raffaella Gothe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ruth Schwarzer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Annette Conrads-Frank

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Petra Schnell-Inderst

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Technology Assessment in Health Care

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

371-383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

15 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

A systematic review of taxane-containing regimens for metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

A perspective on surrogate endpoints in controlled clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

A perfect correlate does not a surrogate make

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Surrogate end points in clinical trials: are we being misled?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Quality-of-life assessment in clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Does chemotherapy improve survival in advanced breast cancer? A statistical overview

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

The Measurement of Observer Agreement for Categorical Data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Perspective: validating surrogate markers--are we being naive?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4744081

Surrogate endpoints: wishful thinking or reality?

28 June 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Endpoints for agents that slow tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Assessing the measure of a new drug: is survival the only thing that matters?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella I

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Criteria for the validation of surrogate endpoints in randomized experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

Surrogate Endpoints And FDA’s Accelerated Approval Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

21 January 2018

1 reference

12 December 2020

Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281

1 reference

12 December 2020

Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO)

1 reference

12 December 2020

Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

1 reference

12 December 2020

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

1 reference

12 December 2020

Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer

1 reference

12 December 2020

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

12 December 2020

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

1 reference

12 December 2020

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

1 reference

12 December 2020

When you look matters: the effect of assessment schedule on progression-free survival

1 reference

12 December 2020

The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080495

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1017/S0266462308080495

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18828930%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PubMed publication ID

18828930

1 reference